3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
128
Lymphoma
107
Lymphoma, Large B-Cell, Diffuse
96
Leukemia
55
Burkitt Lymphoma
50
Lymphoma, Non-Hodgkin
49
Lymphoma, Follicular
37
Lymphoma, Mantle-Cell
33
Hodgkin Disease
25
Retinoblastoma
16
Recurrence
16
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
16
Lymphoma, T-Cell, Peripheral
16
Lymphoma, Large-Cell, Anaplastic
16
Central Nervous System Neoplasms
16
Neuroblastoma
15
Lymphoma, Large-Cell, Immunoblastic
15
Lymphoma, B-Cell
15
Sarcoma
13
Rhabdomyosarcoma
12
Lymphoma, B-Cell, Marginal Zone
12
Neoplasms
11
Medulloblastoma
11
Immunoblastic Lymphadenopathy
11
Sarcoma, Ewing
10
Lymphoma, T-Cell
10
Leukemia, Lymphocytic, Chronic, B-Cell
9
Leukemia, Biphenotypic, Acute
8
Dendritic Cell Sarcoma, Interdigitating
8
Enteropathy-Associated T-Cell Lymphoma
7
Interventions
Temozolomide
2
lutetium Lu 177 dotatate
1
copper dotatate CU-64
1
Vincristine
1
Valproic Acid
1
Thiotepa
1
Sunitinib
1
Radiotherapy
1
Peripheral Blood Stem Cell Transplantation
1
Melphalan
1
Maintenance Chemotherapy
1
Lutetium-177
1
Lutetium
1
Lomustine
1
Interleukin-12
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Erlotinib Hydrochloride
1
Cisplatin
1
Busulfan
1
Bone Marrow Transplantation
1
Aminolevulinic Acid
1
Amifostine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroectodermal Tumors
×
Vincristine
×
Clear all
NCT01614132
2020-03-31
NOA-07
University of Regensburg
Phase 1/2
Completed
33 enrolled